LifeVantage Corporation (Nasdaq: LFVN) reported financial results for the first quarter of fiscal 2027, which ended September 30, 2026. The company announced a 22.0% decrease in total revenue compared to the prior year period.
For the quarter ended September 30, 2026, LifeVantage reported total revenue of $37.1 million. This figure represents a decline from $47.6 million in the same quarter of the previous fiscal year. The company noted that a $0.4 million negative impact from foreign currency exchange rates contributed to the decline.
Revenue performance varied by region. Revenue in the Americas decreased by 22.2% to $29.0 million. Revenue in the Asia/Pacific & Europe region decreased by 21.2% to $8.2 million, which included a $0.4 million negative impact from foreign currency.
The decline in revenue was primarily attributed to lower active accounts and decreased sales of the MindBody GLP-1 System. These factors were partially offset by sales from the LoveBiome product line, which the company acquired in October 2025.
On a per-share basis, the company reported a net loss of $0.02 for the quarter. This compares to a net income of $0.17 per diluted share in the prior year period. Adjusted earnings per diluted share were reported at $0.05, down from $0.18 a year ago.
Adjusted EBITDA for the quarter was $1.9 million, or 5.2% of revenue. This is a decrease from $3.9 million, or 8.2% of revenue, in the prior year period.
The company also reported its balance sheet position as of September 30, 2026. Cash and cash equivalents totaled $13.7 million. There was no debt outstanding. The company generated $0.5 million of cash from operations during the quarter, a decrease from $2.3 million used in operations in the prior year period.
Regarding share repurchases, LifeVantage did not repurchase any shares of common stock during the quarter. As of September 30, 2026, $58.5 million remained available under the company's $60 million share repurchase authorization.
